Trial Profile
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- 01 Apr 2023 Results (n=22) reporting safety and efficacy data from an expansion cohort in triple negative breast cancer (TNBC) of this trial published in the Breast Cancer Research and Treatment
- 02 Jun 2015 Results (n=27) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.